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Review Article

Hypercalcemia of Malignancy: An Update
on Pathogenesis and Management
Aibek E. Mirrakhimov
Department of Medicine, University of Kentucky School of Medicine, 800 Rose Street, Lexington, KY 40536, USA

Abstract
Hypercalcemia of malignancy is a common finding typically found in patients with advanced stage cancers. We aimed to provide an
updated review on the etiology, pathogenesis, clinical presentation, and management of malignancy-related hypercalcemia. We searched
PubMed/Medline, Scopus, Embase, and Web of Science for original articles, case reports, and case series articles focused on hypercalcemia
of malignancy published from 1950 to December 2014. Hypercalcemia of malignancy usually presents with markedly elevated calcium
levels and therefore, usually severely symptomatic. Several major mechanisms are responsible for the development of hypercalcemia of
malignancy including parathyroid hormone-related peptide-mediated humoral hypercalcemia, osteolytic metastases-related hypercalcemia,
1,25 Vitamin D-mediated hypercalcemia, and parathyroid hormone-mediated hypercalcemia in patients with parathyroid carcinoma and
extra parathyroid cancers. Diagnosis should include the history and physical examination as well as measurement of the above mediators of
hypercalcemia. Management includes hydration, calcitonin, bisphosphonates, denosumab, and in certain patients, prednisone and cinacalcet.
Patients with advanced underlying kidney disease and refractory severe hypercalcemia should be considered for hemodialysis. Hematology
or oncology and palliative care specialists should be involved early to guide the options of cancer targeted therapies and help the patients
and their closed ones with the discussion of comfort-oriented care.
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Introduction
Hypercalcemia is defined as an increase in the serum
calcium level above the upper limit of normal for
a given reference value used in a laboratory.[1] The
differential diagnosis of hypercalcemia includes multiple
pathologic entities but is focused primarily on primary
hyperparathyroidism and hypercalcemia of malignancy
given the highest prevalence of these etiologies.[1] It
seems that hypercalcemia of malignancy is a common
finding in patients with cancer, affecting up to 44.1% of
patients.[2,3] It is also important to note that hypercalcemia
of malignancy is particularly common in cases of
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advanced stage cancer.[4] Patients with hypercalcemia
of malignancy tend to have limited survival of several
months, and it is not clear whether this poor prognosis is
related to the advanced stage of malignancy associated
hypercalcemia or just simply a marker of underlying
cancer.[5]
It is unclear whether asymptomatic hypercalcemia
heralds the later development of cancer. To answer this
question, Hamilton et al. retrospectively analyzed the
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charts of more than 52,000 patients.[6] The goal of their
work was to study whether a finding of elevated calcium
can predate the development of malignancy. Patients
with hypercalcemia comprised the minority but had
higher rates of cancer diagnosis at 1-year (6.2% compared
to 3.0%). However, the retrospective methodology of
this study should be kept in mind when interpreting
the study results. Another important aspect to mention
briefly is that not all hypercalcemia in cancer patients is
secondary to malignancy, and this is discussed further
in subsequent sections.[7]
The goal of this study is to review the current knowledge
on the etiopathogenesis, clinical presentation, diagnosis,
and treatment of hypercalcemia of malignancy. We
searched PubMed/Medline, Scopus, Embase, and Web
of Science for original articles, case reports, and case
series articles focused on hypercalcemia of malignancy
published from 1950 to December 2014. The search terms
were: Hypercalcemia of malignancy, hypercalcemia,
Vitamin D and hypercalcemia, skeletal metastases
and hypercalcemia, parathyroid hormone (PTH),
PTH-related peptide (PTHrP), and the combination
of these. The reference lists of the identified articles
were further screened for potentially relevant articles
that could be overlooked by an electronic search. The
search methodology was adapted from the scientific
search guidelines published in 2011.[8] We start with a
physiological overview of calcium metabolism. Second,
we discuss the etiology and pathogenesis of hypercalcemia
of malignancy. Third, we review the clinical presentation
of hypercalcemia. Fourth, the diagnostic approach to
hypercalcemia is addressed. Finally, the management of
hypercalcemia of malignancy is discussed.

Normal Regulation of Calcium Metabolism
Calcium is an essential element that participates
in various biochemical reactions, including muscle
contraction, coagulation and bone development among
others.[9] Calcium is absorbed predominantly in the
small intestine, and it is necessary to note that only
10-20% of ingested calcium is absorbed, the remainder
being excreted with the stool.[9] Calcium in the body
is present in two major compartments: Bone, where
calcium is stored as hydroxyapatite salt that comprises
the major part of body calcium, and plasma.[10] In plasma,
serum calcium is present in several forms, such as free
or ionized calcium, which is actually a physiologically
active form corresponding to approximately 45% of
serum calcium, with 65% of calcium being bound to
various carriers, such as albumin (40% of calcium), citric
acid, sulfate, and phosphate.[10]
Several hormonal systems regulate calcium absorption
and metabolism. When calcium levels drop below
484

10 mg/dl, this activates calcium-sensing cells in the
parathyroid glands to stimulate the release of PTH.
PTH release reaches a peak when calcium falls below
7.5 mg/dl.[9] When the calcium level is above 10 mg/dl, the
secretion of PTH is minimal. PTH has several important
actions focused on the increase of serum calcium.
First, PTH activates the 1-alpha-hydroxylase enzyme
located in the renal proximal tubules, which in turn
converts 25-hydroxyvitamin D into the more active
1,25-dihydroxyvitamin D.[10] Second, PTH stimulates
calcium reabsorption in the distal part of the nephron
(thick ascending limb of the loop of Henle and distal
convoluted tubule) and renal phosphorus excretion.
Third, PTH leads to calcium mobilization from the bone
with the help of 1,25-dihydroxyvitamin D. All these
actions aim to increase calcium concentrations, bringing
them back to normal.
Another key player in normal calcium metabolism
is Vitamin D. Vitamin D or cholecalciferol sources
in the body include synthesis in the skin from
7-dehydrocalciferol under the influence of
ultraviolet light and dietary intake.[10] Subsequently,
25-hydroxycholecalciferol will be converted
into 25-dihydroxycholecalciferol in the liver by
25-hydroxyvitamin D3 1-alpha-hydroxylase.
Eventually, 25-dihydroxycholecalciferol will be
delivered into kidneys where it can be activated by the
aforementioned 1-alpha-hydroxylase enzyme (which is
activated by PTH) into 1,25-dihydroxycholecalciferol.[10]
1,25-dihydroxycholecalciferol in turn increases the
absorption of calcium and phosphate in the gastrointestinal
tract, decreases the renal excretion of calcium and
phosphate, and with the participation of PTH leads
to increased calcium release from the bone and
subsequent bone mineralization.[9] It is important to
note that 1,25-dihydroxycholecalciferol is deactivated
by the 24,25-hydroxylase enzyme in the kidneys.[10]
From a normal physiology perspective, it is important
to mention a thyroid hormone, calcitonin, which is
produced by thyroid C cells.[10] Calcitonin release is
augmented when calcium concentration increases and
limits bone remodeling and subsequent calcium release
from the bone and calcium reabsorption in the kidneys.
However, tumors secreting calcitonin, such as medullary
thyroid cancer, do not lead to low calcium levels.[10]
Nevertheless, calcitonin may be used in the management
of hypercalcemia of malignancy (as discussed below).
A possible explanation for the efficacy of calcitonin in
patients with malignancy-related hypercalcemia could
be related to secondary overzealous bone resorption and
calcium release in these patients.
Finally, it is necessary to discuss briefly the different roles
of major bone cells and their interplay in bone turnover
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and calcium release. For this purpose, we focus on two
cellular types: Osteoblasts and osteoclasts. Osteoblasts
derive from mesenchymal cells and osteoclasts originate
from monocyte lineage that migrates into the bone
environment from the bloodstream. [10,11] Osteoclast
precursor cells carry the receptor activator of nuclear
factor-κ B (RANK). [10,11] Osteoblasts in turn secrete
a ligand for RANK (RANKL), which stimulates the
maturation of osteoclast precursors and the formation
of mature osteoclasts capable of bone remodeling
and calcium release.[11,12] Factors that promote bone
remodeling and calcium release from the bone stimulate
osteoblasts through RANKL release and subsequent
activation of osteoclasts. Factors that exert the opposite
effects on bone turnover (such as estrogens) stimulate
the release of osteoprotegerin from osteoblasts, binding
RANKL, and preventing it from binding to RANK on
the osteoclast precursor cell.[12-14]
In conclusion, the intricate interaction between calcium
levels, PTH, Vitamin D, and bone cells regulates bone
metabolism and calcium release from the bones.

Etiology and Pathobiology of Hypercalcemia
of Malignancy
There are several major mechanisms of hypercalcemia
of malignancy, which are discussed here. First, the
major mechanism, accounting for approximately 80% of
malignancy-related hypercalcemia, is mediated by the
production of PTHrP.[4] It is also important to note that
PTHrP is normally produced and secreted by various
cells, and normal breast cells in particular.[15] Furthermore,
PTHrP under normal physiological conditions
participates in the development of various tissues,
facilitates transplacental calcium transport, and promotes
calcium transfer to breast milk.[15] Both PTH and PTHrP
act on the same receptors and their effects consistently
overlap. Indeed, the biochemical structure of PTHrP
greatly resembles that of PTH.[15] However, PTHrP does
not seem to have a major influence on the production
of 1,25-dihydroxycholecalciferol.[15] Therefore, PTHrP
acts on osteoblasts, leading to enhanced synthesis of
RANKL, with subsequent activation of osteoclasts
and bone resorption with calcium release into the
bloodstream. Increased renal calcium reabsorption is
another mechanism through which PTHrP leads to
hypercalcemia. Squamous cell cancers, urinary tract
cancers (renal cancer and bladder cancer), breast cancer,
nonHodgkin’s lymphoma, and ovarian cancer account
for the majority of malignancies leading to hypercalcemia
via PTHrP.[4]
The second mechanism by which malignancies cause
hypercalcemia includes osteolytic metastases and

excessive calcium release from bone, accounting
for approximately 20% of malignancy-related
hypercalcemia.[4] Breast cancer and multiple myeloma
account for the vast majority of the cases of osteolytic
hypercalcemia.[4] It is interesting to note that metastatic
breast cancer cells may produce PTHrP locally, without
a major increase in serum PTHrP.[16] Local factors that are
released in the presence of metastatic bone lesions include
transforming growth factor β, which stimulates PTHrP to
be produced locally from metastatic breast cancer cells.[17]
In turn, the elevation of calcium further stimulates local
PTHrP release, generating a vicious cycle. In the case of
multiple myeloma, the local release of various cytokines,
such as RANKL, interleukin-3 and -6, facilitate bone
remodeling and resultant hypercalcemia.[18] It is worth
noting that a very small proportion of patients with
multiple myeloma and hypercalcemia do not have true
hypercalcemia.[19] This apparent increase in calcium is
mediated by calcium binding to paraprotein secreted
by multiple myeloma cells.[19] It should be borne in mind
that such patients will typically have a mild elevation
in total calcium with normal ionized levels and will not
have any symptoms of hypercalcemia.
The third mechanism includes ectopic activity of
1-alpha-hydroxylase and the formation of
1,25-dihydroxycholecalciferol, common in lymphomas
and in some ovarian germ cell tumors.[4] The fourth
mechanism by which cancer can lead to hypercalcemia
includes ectopic production of PTH,[20] or in rare cases
PTH can be secreted by parathyroid carcinoma.[21] Small
cell lung cancer and adenocarcinoma can mediate
hypercalcemia via such mechanism.[20] Furthermore, it
is important to note that some patients with apparent
hypercalcemia of malignancy will have evidence of
primary hyperparathyroidism.[22-24]
In conclusion, there are several major mechanisms that
account for malignancy-related hypercalcemia, including
the excessive tumor production of PTHrP, osteolytic
metastatic disease, ectopic activity of 1-alpha-hydroxylase
and the production of 1,25-dihydroxycholecalciferol, the
excessive production of PTH by parathyroid carcinoma
and extra parathyroid malignancies, and finally
hypercalcemia due to paraprotein binding. The major
mechanisms of malignancy-related hypercalcemia are
emphasized in Figure 1.

Clinical Presentation of Hypercalcemia
For a long time, clinicians used mnemonics, such as
“stones, bones, abdominal moans, and psychic groans”
to memorize the major clinical manifestations of
hypercalcemia.[4] Indeed, the major systems affected by
hypercalcemia include neuropsychiatric, gastrointestinal,
and renal. It is important to note that at least two factors

North American Journal of Medical Sciences | Nov 2015 | Volume 7 | Issue 11 |

485

[Downloaded free from http://www.najms.org on Friday, November 27, 2015, IP: 202.164.43.126]

Mirrakhimov: Hypercalcemia of malignancy

play a role in the development of clinically overt
hypercalcemia, such as the degree of hypercalcemia
and the rapidity of its development. Patients with
hypercalcemia of malignancy typically have a higher
degree of hypercalcemia and develop it over a shorter
period, which is why these patients are usually more
symptomatic than patients with other etiologies of
hypercalcemia.[4]
Neurocognitive symptoms of hypercalcemia may
include some behavioral disturbances, such as anxiety,
mood changes and a decrease in cognitive function,
which are typical of milder cases of hypercalcemia
(degrees of hypercalcemia are discussed further in
the next section). However, as patients with cancer
generally present with higher values of calcium, they
may develop more severe presentations, such as changes
in mental status, including coma. [25] Furthermore,
patients with malignancy-related hypercalcemia
may develop a syndrome of posterior reversible
leukoencephalopathy (PRES), which is characterized
clinically by the development of headaches, seizures
and imaging findings of subcortical edema.[26,27] Several
pathobiological factors such as cerebral vasoconstriction,
endothelial dysfunction, and systemic inflammation may
precipitate PRES in such groups of patients.[27]

may mimic ST-segment elevation myocardial infarction
on the ECG. [33-35] Cardiac catheterization has been
found to be negative for coronary atherosclerosis[32,33]
and in one case, myocardial infarction has been ruled
out with serial cardiac enzymes (troponin and creatine
kinase-MB fraction) measurements. [34] Furthermore,
patients with severe hypercalcemia may develop
malignant ventricular arrhythmias such as ventricular
fibrillation.[36]
Also, it is important to bear in mind that most patients
with malignancy-related hypercalcemia have clinically
overt cancer (either retrospectively or newly diagnosed).
Therefore, in a patient without documented malignancy
but with severe newly diagnosed hypercalcemia, it
is important to take a focused history (e.g., smoking
history, exposure to carcinogens, family history of
cancer, prior personal history of cancer, presence of
cough, unintentional weight loss, etc.), and perform
a thorough physical examination (e.g., breast mass in
a female patient, abdominal mass on palpation, etc.)
in order to guide a further diagnostic work-up. A
summary of the clinical features of hypercalcemia is
presented in Table 1.

Renal manifestations of hypercalcemia consist of
nephrogenic diabetes insipidus with resultant polyuria,
renal vasoconstriction, distal renal tubular acidosis,
and in more chronic cases, nephrolithiasis, tubular
dysfunction, and chronic renal failure.[28,29]
Elevated calcium levels also affect the gastrointestinal
system. Mild elevation of calcium may present as
anorexia and constipation.[1] Patients with more advanced
hypercalcemia may develop nausea and vomiting.
Thus, all patients with clinically overt hypercalcemia
are volume depleted, which is explained by the renal
effects of hypercalcemia (polyuria) and the decreased
oral intake with associated nausea and vomiting. Other
possible gastrointestinal manifestations of hypercalcemia
include pancreatitis and peptic ulcer disease. [30,31]
However, it is important to note that peptic ulcer disease
has predominantly been reported in hypercalcemia
due to primary hyperparathyroidism.[30] Nevertheless,
clinicians should bear in mind this potential complication
in a patient with hypercalcemia and clinical findings
suggestive of upper gastrointestinal bleeding (such as
black tarry stools or frank bloody stools, epigastric pain,
dropping hematocrit, and hemodynamic instability).
Another organ system that may be affected by elevated
calcium is the cardiovascular system. Patients with
hypercalcemia typically have a shortened QT interval on
the electrocardiogram (ECG).[32] Severe hypercalcemia
486

Figure 1: Etiobiology of hypercalcemia of malignancy

Table 1: Clinical features of hypercalcemia
Organ system

Clinical features

Neurologic

Fatigue, altered mental status
including coma, posterior reversible
leukoencephalopathy
Nausea, vomiting, constipation, peptic ulcer
disease, and pancreatitis
Short QT interval on ECG, ST segment
abnormalities including ST segment
myocardial infarction mimic, malignant
ventricular arrhythmias, and hypertension
Nephrogenic diabetes insipidus, acute
kidney injury

Gastrointestinal
Cardiovascular

Renal

ECG = Electrocardiogram
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Diagnostic Approach to Hypercalcemia
As discussed above, serum calcium is the sum of
carrier-bound calcium that is not physiologically active
and ionized calcium, which is the active form of serum
calcium.[9] Thus, when evaluating elevated serum calcium
levels, it is essential to keep this in mind, especially as
most general chemistry tests measure total calcium
rather than free ionized calcium. Therefore, conditions in
which the alteration of serum protein levels is a feature
may have abnormal total calcium levels, but may not
have any changes in physiologically important ionized
calcium levels.[37] For example, malnourished patients or
patients with a protein-losing condition (e.g., nephrotic
syndrome, protein-losing enteropathy, etc.) may be
found to have low total calcium levels due to a decrease
in albumin levels, a major carrier for calcium in the blood
(it is possible that some patients with low total calcium
may have elevated ionized calcium due to underlying
conditions such as cancer). On the other hand, patients
with severe dehydration may have elevated protein
levels and hence, elevated calcium levels.[37]
Therefore, it is advised to confirm elevated serum
calcium with a repeat test. Nevertheless, it is reasonable
to start treatment with intravenous (IV) fluid hydration
for markedly elevated calcium levels, especially with
associated typical symptoms, while awaiting a repeat
calcium measurement. Several approaches can be
used to distinguish between true hypercalcemia and
pseudohypercalcemia. First, it is possible to estimate
the levels of free or ionized calcium after adjustment
for albumin levels. Correction of calcium for albumin
level should be done in patients with abnormal (both
low and elevated levels) albumin and can be calculated
via this formula: Calcium (mg/dl) + 0.8 (4.0 − patient’s
albumin level); however, numerous free online
calculators are available which can be used in clinical
practice. Second, it is possible to measure ionized
calcium levels directly, and this may be the preferred
method given its higher sensitivity, as albumin is the
major but not the only carrier. [38] Most laboratories
in the United States of America use a range of total
serum calcium levels of 8.5-10.2 mg/dl (please follow
your institution’s range for serum calcium). We divide
hypercalcemia into mild hypercalcemia with serum
calcium levels <12 mg/dl, moderate hypercalcemia with
serum calcium levels between 12 mg/dl and 14 mg/dl,
and severe hypercalcemia with serum calcium levels
above 14 mg/dl.
From a clinical perspective, most cases of hypercalcemia
are due to cancer or primary hyperparathyroidism.[1,37]
However, as already discussed, most patients with
cancer have greater levels of calcium than patients with
hypercalcemia secondary to other causes and are more

symptomatic. Furthermore, the diagnosis of cancer will
be obvious in a great number of cases. Nevertheless,
from the conceptual perspective, hypercalcemia can be
divided into PTH-dependent and PTH-independent
(after confirmation of truly elevated calcium). [1,37]
PTH-dependent causes largely include primary
hyperparathyroidism, PTH production by malignant
cells (parathyroid carcinoma and extra parathyroid
cancers) and familial hypocalciuric hypercalcemia.[1,37]
Other causes of hypercalcemia (including cancer-related)
constitute PTH-independent hypercalcemia.
The next step in evaluating a case with suspicious
features of malignancy-related hypercalcemia consists
of measuring both PTH and PTHrP. The reason for the
PTH measurement in such cases includes the fact that
patients with cancer may have a greater prevalence
of primary hyperparathyroidism, and some patients
with cancer may have primary hyperparathyroidism
as a sole cause of hypercalcemia.[7,22,39] In cases in which
malignancy is the only cause of hypercalcemia, serum
PTH levels should be suppressed or low normal. High
normal PTH levels in the setting of hypercalcemia are
inappropriate and suggest the presence of parathyroid
hyperfunction.[1,37] Given the fact that some cancers may
produce PTH ectopically,[20,40] imaging tests may be used
to evaluate the parathyroid glands for hyperfunction in
selected cases.[41,42] PTHrP levels will be elevated in cases
of humoral hypercalcemia of malignancy. However,
in some cases, in which the diagnosis of cancer (e.g.,
known advanced squamous cell carcinoma of the
lung) is well known, the measurement of PTHrp levels
may be omitted. From a management perspective, the
degree of PTHrP elevation may predict response to
bisphosphonates and mortality.[43-46]
If the PTHrP levels are low, the next step should include
measurement of 1,25-dihydroxyvitamin D levels to
screen for Vitamin D-mediated hypercalcemia, which is
typically seen in lymphomas. In patients with low levels
of PTH, PTHrp, and 1,25-dihydroxyvitamin D, one might
consider hypercalcemia due to osteolytic metastases
as the cause of malignancy-related hypercalcemia.
However, it is important to note that more than one
mechanism of malignancy-associated hypercalcemia can
be seen in a particular patient.[47]
Furthermore, an approach to hypercalcemia should be
thorough and include the review of medications.[1,37]
Medications such as lithium, thiazide diuretics, and
Vitamin A and D supplements should be discontinued
if possible. These medications might not explain the
hypercalcemia, but have the potential to make it worse.
In conclusion, an approach to hypercalcemia consists
of confirming that hypercalcemia is true. Second,
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measurements of PTH and PTHrp should start the
laboratory work-up. Serum 1,25-dihydroxyvitamin D
measurement should be undertaken when OTH and
PTHrp are decreased. Hypercalcemia secondary to
osteolytic metastases should be considered when the
laboratory values mentioned above are decreased.
Furthermore, a review of home medications should be
done and the discontinuation of medications capable
of causing hypercalcemia should be considered.
A diagnostic flowchart is presented in Figure 2.

Management of Hypercalcemia
The management of hypercalcemia is based on the
presence of characteristic symptomatology and the
severity of calcium elevation. Patients with hypercalcemia
of malignancy are typically symptomatic and have
markedly elevated calcium levels. Thus, patients with
hypercalcemia will generally need to be managed with
urgency, and hypercalcemia of malignancy in many cases
represents an oncologic emergency.
The treatment options for hypercalcemia include IV
hydration, calcitonin, bisphosphonates, denosumab,
gallium nitrate, prednisone, and hemodialysis. Each
therapeutic modality is discussed in greater detail
in this section. It is also important to emphasize that
given the overall poor prognosis of many patients with
malignancy-related hypercalcemia, a palliative care
team should be involved in the care of the patient and
the goals of care should be discussed with the patient or
his or her surrogate.
As discussed above, patients with hypercalcemia
are dehydrated by default due to poor oral intake
secondary to nausea, vomiting, altered mental status, and
hypercalcemia-induced nephrogenic diabetes insipidus.

Figure 2: Diagnostic flowchart on the work up of hypercalcemia
488

Furthermore, volume contraction in itself compromises
renal clearance of calcium due to hypovolemia-mediated
increased calcium reabsorption in the kidneys.[47] Several
factors, such as the presence of underlying cardiorenal
disease, should be borne in mind when considering IV
hydration. Isotonic crystalloid solutions (e.g., normal
saline) should be used for IV hydration.[48] We typically
start patients with advanced hypercalcemia at a rate of
around 200-300 ml/h and reassess them periodically
for signs of fluid overload (shortness of breath, edema,
etc.). The rate of IV hydration should be decreased in
patients with underlying cardiac and renal disease to
minimize the risk of symptomatic fluid overload. It
is important to mention that the routine use of loop
diuretics such as furosemide is not recommended due
to the development of volume depletion and electrolyte
abnormalities.[49] Moreover, there are much more specific
therapies targeting hypercalcemia. The use of furosemide
should be reserved for patients who develop signs of
fluid overload while receiving IV hydration.
However, IV hydration alone is not enough to correct
severe hypercalcemia. The second option that should be
considered in the management of severe hypercalcemia
is calcitonin.[50] It is important to emphasize that only
intramuscular or subcutaneous administration should
be used given the fact that intranasal calcitonin does
not seem to be effective in hypercalcemia for reasons
that are not yet clear.[51] The typical dose of calcitonin for
the management of hypercalcemia ranges from 4 IU/kg
to 8 IU/kg.[50,52] The drop in serum calcium typically
occurs within 4 h after administration and one should
expect a maximal drop in calcium of 2 mg/dl.[50,52] The
dosing intervals range from every 6 h to every 12 h. It is
important to note that both the dose and administration
frequency are tailored to the hypocalcemic response.
The duration of administration is typically limited
to 48 h given the development of tachyphylaxis and
decreased responsiveness.[50,52] Calcitonin seems to work
via the inhibition of osteoclast activity and an increase
in renal calcium excretion.[53] Calcitonin is an important
adjunctive medication in the management of severe
hypercalcemia given its rapid onset of action and serves
as a bridge while other treatment modalities are reaching
its therapeutic effect.
Bisphosphonates comprise a group of medications
that are analogs of natural pyrophosphate, which is
an essential part of bones.[54,55] Bisphosphonates are
used in many situations, such as the treatment and
prevention of osteoporosis, Paget’s disease of bone,
metastatic bone disease, and hypercalcemia. This
section discusses the use of bisphosphonates in the
management of symptomatic hypercalcemia, particularly
hypercalcemia of malignancy. For greater detail on the
role of bisphosphonates in the management of other
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diseases, the reader is referred to review articles on this
topic.[54,55] Bisphosphonates are typically subdivided into
two groups: First generation and second-generation.
The first-generation or nonnitrogen-containing
bisphosphonates include etidronate and clodronate,
which are less commonly used nowadays.[54,55] The secondgeneration or nitrogen-containing bisphosphonates
include such medications as alendronate, risedronate,
ibandronate, pamidronate, and zoledronic acid, which
are generally more potent than the first-generation
bisphosphonates. The mechanisms of action include the
impairment of osteoclast-mediated bone resorption, the
arrest of osteoclast development, osteoclast apoptosis,
and a decrease in osteoblast apoptosis.[54,55]
Zoledronic acid, ibadronate, pamidronate, and less often
etidronate are used for the treatment of hypercalcemia
of malignancy. Zoledronic acid is the most potent
agent among the bisphosphonates, as shown in a study
that compared zoledronic acid to pamidronate.[56] The
typical dose is 4 mg administered IV over 15-30 min.
Pamidronate and ibandronate are less potent agents
than zoledronic acid but have similar efficacy when
compared to each other.[57] The typical dose range for
pamidronate is from 60 mg to 90 mg administered
IV over 2 to 24 h. However, a shorter duration of
pamidronate administration, such as 4 h, may be as safe
as the longer duration of administration.[58] Ibandronate
has a dose range from 2 mg to 6 mg administered IV,
but it is important to mention that the use of ibandronate
is off-label for the treatment of hypercalcemia.[57] These
drugs have been used in patients with underlying kidney
dysfunction and hypercalcemia of malignancy. For
example, zoledronic acid has been used in patients with
creatinine of 4.5 mg/dl[56] and pamidronate in patients
with creatinine of 1.5 mg/dl and higher.[59] Nevertheless,
it is advised to decrease the doses and duration of
administration in patients with underlying renal disease.
However, bisphosphonates seem to be safe in patients
with end-stage renal disease on hemodialysis.[60,61] The
onset of the calcium-lowering effect is within 2-4 days
after the administration.
Bisphosphonates are usually well-tolerated, but several
classic side effects have been described. Patients taking
bisphosphonates commonly experience flu-like symptoms;
other potential side effects include ocular symptoms, acute
kidney injury, new-onset nephrotic syndrome, esophageal
inflammation (typically for orally administered drugs),
and very rarely osteonecrosis of the jaw.[54,55] Osteonecrosis
of the jaw is typically reported in patients with multiple
myeloma or metastatic bone disease receiving high potency
bisphosphonates, such as zoledronic acid and denosumab,
which is a monoclonal antibody to RANKL.[62] However,
patients who develop this complication typically receive
the aforementioned medications for at least 4 months. Thus,

osteonecrosis of the jaw is not typically a problem during
acute management of hypercalcemia of malignancy. It
is important to mention that bisphosphonates are given
once, and the dose should be repeated no earlier than
1-week after the administration of the first dose. Moreover,
as mentioned above, patients with marked elevation of
PTHrP may be more resistant to the hypocalcemic effects
of bisphosphonates.[43-46]
Denosumab is a human monoclonal antibody to
RANKL, thus working through decreasing osteoclast
activity and bone resorption.[63] Denosumab has been
shown to be effective in hypercalcemia refractory to
bisphosphonates.[21,64-66] Furthermore, denosumab has an
advantage to bisphosphonates in that it is not removed by
the kidneys. It is important to mention that denosumab
has been shown to improve renal function in patients
with multiple myeloma and hypercalcemia.[67,68] However,
the effect of denosumab may be more pronounced in
patients with renal failure, and some have suggested
a lower dose (half) in the case of renal failure.[68] The
typical dose of denosumab is 120 mg subcutaneously,
and the dose should be repeated no earlier than 1-week
following the first administration.[69] The hypocalcemic
effect of denosumab is typically seen within 2-4 days
after the administration. The use of denosumab for the
management of hypercalcemia of malignancy is off-label
and should be reserved for cases of severe hypercalcemia
refractory to more conventional treatment.
Common side effects attributed to denosumab include
bone pain, nausea, diarrhea, shortness of breath, and in
rare instances osteonecrosis of the jaw, which is usually
seen in patients treated with denosumab for at least
several months, thus making it less important in the
acute setting of hypercalcemia of malignancy.[62,63] Data
on denosumab and infectious risk are controversial, but
a major clinical study failed to demonstrate an infectious
risk in patients treated with denosumab.[70]
Patients with lymphomas and some ovarian germ tumors
who overproduce 1,25-dihydroxycholecalciferol can be
treated with prednisone to reduce the gastrointestinal
absorption of calcium.[71] The typical dose of prednisone
is 20-40 mg orally.[71] Common side effects of prednisone
use include hyperglycemia, hypertension, psychiatric
disturbances, muscle weakness, peptic ulcer disease,
and many others.[72]
Other pharmacological options for the treatment of
hypercalcemia include cinacalcet and gallium nitrate.
Cinacalcet works by decreasing the production of
PTH[73] and is commonly used in the management of
hypercalcemia secondary to parathyroid carcinoma.[73,74]
It is unclear whether it can be used in a rare extra
parathyroid cancer patient with ectopic production of

North American Journal of Medical Sciences | Nov 2015 | Volume 7 | Issue 11 |

489

[Downloaded free from http://www.najms.org on Friday, November 27, 2015, IP: 202.164.43.126]

Mirrakhimov: Hypercalcemia of malignancy

PTH. The typical dose range of cinacalcet is from 60 mg to
360 mg orally, and the dose is typically split throughout
the day. Common side effects include nausea, vomiting,
and headaches.
Lastly, gallium nitrate can be used in the treatment of
malignancy-related hypercalcemia via the inhibition of
osteoclast activity and by increasing the renal calcium
clearance.[75-77] The typical dose used in the clinical studies
is 200 mg/m2 administered as a slow IV infusion daily for
5 days.[78,79] Gallium nitrate has been shown to be more
potent than calcitonin, notably in a study of 164 patients
with cancer-related hypercalcemia.[78] The medication was
well tolerated with a small percentage of treatment-related
anemia and acute kidney injury being observed.[78,79]
However, gallium nitrate production was discontinued
by the manufacturer in 2012, making it unavailable for the
treatment of malignancy-related hypercalcemia.
Finally, patients with refractory severe hypercalcemia
and underlying cardiorenal diseases that cannot safely
be hydrated should be considered for hemodialysis.[80,81]

It is also important to consult with a hematologist or
oncologist regarding the cancer-targeted treatment
options for every patient, and a palliative care
professional to improve the patient’s symptoms and
explore comfort care options in the right clinical
scenario.
In conclusion, the treatment of symptomatic
malignancy-related hypercalcemia should start with
aggressive IV hydration in patients without significant
renal or cardiac disease. Calcitonin can be used given
its prompt effect and favorable side-effect profile.
Bisphosphonates should be administered concurrently as
the hypocalcemic effect starts within 2-4 days. Prednisone
can be used in patients with an overproduction of
1,25-dihydroxycholecalciferol and cinacalcet should be
considered in patients with an overproduction of PTH
(e.g., parathyroid carcinoma). Patients with refractory
hypercalcemia should be considered for denosumab
therapy and lastly for hemodialysis. A summary of the
therapeutic options for the treatment of hypercalcemia
is presented in Table 2.

Table 2: Summary of pharmacologic therapeutic options for the management of hypercalcemia
Agent

Typical dose

Mechanism of
action

Normal saline

200-300 milliners/
hour, lower rate
in patients with
underlying cardiac
and kidney disease
4-8 international
units/kg
subcutaneously or
intramuscularly

Bisphosphonates

Zoledronic acid 4
mg administered
IV over 15 min;
pamidronate 60-90
mg administered
IV over 2-24 h;
ibandronate 2-6 mg
administered IV
over 1-2 h

Denosumab

120 mg
subcutaneously

Zoledronic acid: Do not use
in patients with creatinine
>4.5 mg/dl (consider
increasing the infusion
duration in patients with
kidney disease); no need
for hepatic adjustment
Pamidronate and
ibandronate: Do not use if
glomerular filtration rate
is <30; no need for hepatic
adjustment
Impairs
No need for renal and
osteoclast activity hepatic adjustment.
Consider half dose for
patients with renal disease
to decrease the risk of
hypocalcemia

Calcitonin

490

Modification based on
underlying renal and
liver disease

Onset of action

Common side
effects

Volume
Consider lower rate in
repletion,
patients with underlying
increased renal
renal disease
calcium clearance

Within hours of
administration

Volume overload,
non-anion
gap metabolic
acidosis

Inhibition of
osteoclast activity
and increase in
renal calcium
clearance
Inhibition
of osteoclast
acitivity,
osteoclast
apoptosis and
improved
osteoblast
survival

Within 4 h of
administration.
Tachyphylaxis
develops after 48 h

Nausea, rhinitis,
hypersensitivity
reactions

Within 2-4 days
after administration.
Do not repeat
administration
earlier than 1 week
after the previous
IV infusion

Flu-like
symptoms, bone
aches, nephrotic
syndrome, acute
kidney injury,
osteonecrosis of
the jaw

Within 2-4 days
after administration.
Do not repeat
administration
earlier than 1 week
after the previous
dosing

Bone pain,
nausea, diarrhea,
shortness
of breath,
osteonecrosis
of the jaw and
possibly increase
in the risk of
infections after
long-term use

No dosage adjustment is
needed
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Conclusion

9.

Hypercalcemia of malignancy is a common finding
typically in patients with advanced stage cancers.
Hypercalcemia of malignancy usually presents with
markedly elevated calcium levels and patients are
therefore usually severely symptomatic. Several major
mechanisms are responsible for the development of
hypercalcemia of malignancy, including PTHrP-mediated
humoral hypercalcemia, osteolytic metastases-related
hypercalcemia, 1,25-dihydroxyvitamin D mediatedhypercalcemia, and PTH-mediated hypercalcemia
in patients with parathyroid carcinoma and extra
parathyroid cancers. Diagnosis should include the
history of the patient and physical examination, as
well as the measurement of the above mediators of
hypercalcemia. Management includes IV hydration,
calcitonin, bisphosphonates, denosumab, and prednisone
and cinacalcet in certain patients. Patients with advanced
underlying kidney disease and refractory severe
hypercalcemia should be considered for hemodialysis.
Hematology or oncology and palliative care specialists
should be involved early on to guide the selection of
cancer-targeted therapies and help the patients and
surrogates with comfort care and discussing potential
comfort care options.

10.
11.

12.
13.

14.
15.
16.
17.

18.
19.

Financial support and sponsorship
Nil.

20.

Conflicts of interest
There are no conflicts of interest.

References
1.
2.
3.

4.
5.

6.

7.

8.

Endres DB. Investigation of hypercalcemia. Clin Biochem
2012;45:954-63.
Burt ME, Brennan MF. Incidence of hypercalcemia and
malignant neoplasm. Arch Surg 1980;115:704-7.
Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF.
Incidence of hypercalcemia in patients with malignancy referred
to a comprehensive cancer center. Cancer 1993;71:1309-12.
Stewart AF Clinical practice. Hypercalcemia associated with
cancer. N Engl J Med 2005;352:373-9.
Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT.
Cancer-associated hypercalcemia: Morbidity and mortality.
Clinical experience in 126 treated patients. Ann Intern Med
1990;112:499-504.
Hamilton F, Carroll R, Hamilton W, Salisbury C The risk of
cancer in primary care patients with hypercalcaemia: A cohort
study using electronic records. Br J Cancer 2014;111:1410-2.
Soyfoo MS, Brenner K, Paesmans M, Body JJ. Non-malignant
causes of hypercalcemia in cancer patients: A frequent and
neglected occurrence. Support Care Cancer 2013;21:1415-9.
Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD. Writing
a narrative biomedical review: Considerations for authors,
peer reviewers, and editors. Rheumatol Int 2011;31:1409-17.

21.
22.
23.

24.

25.
26.

27.

Bronner F. Mechanisms of intestinal calcium absorption. J Cell
Biochem 2003;88:387-93.
Hall JE. Guyton and Hall Textbook of Medical Physiology.
12th ed. Saunders, 2010; p. 955-972.
Mellis DJ, Itzstein C, Helfrich MH, Crockett JC. The skeleton:
A multi-functional complex organ: The role of key signalling
pathways in osteoclast differentiation and in bone resorption.
J Endocrinol 2011;211:131-43.
Hofbauer LC, Schoppet M. Clinical implications of the
osteoprotegerin/RANKL/RANK system for bone and
vascular diseases. JAMA 2004;292:490-5.
Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL,
Riggs BL. Role of rank ligand in mediating increased bone
resorption in early postmenopausal women. J Clin invest
2003;111:1221-30.
Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation
and activation. Nature 2003;423:337-42.
Wysolmerski JJ. Parathyroid hormone-related protein:
An update. J Clin Endocrinol Metab 2012;97:2947-56.
Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology
of breast cancer bone metastasis. Cancer Biol Ther 2008;7:3-9.
Johnson RW, Nguyen MP, Padalecki SS, Grubbs BG,
Merkel AR, Oyajobi BO, et al. TGF-beta promotion of
Gli2-induced expression of parathyroid hormone-related
protein, an important osteolytic factor in bone metastasis, is
independent of canonical Hedgehog signaling. Cancer Res
2011;71:822-31.
Roodman GD. Pathogenesis of myeloma bone disease.
J Cell Biochem 2010;109:283-91.
Pearce CJ, Hine TJ, Peek K. Hypercalcaemia due to calcium
binding by a polymeric IgA kappa-paraprotein. Ann clin
biochem 1991;28(Pt 3):229-34.
VanHouten JN, Yu N, Rimm D, Dotto J, Arnold A,
Wysolmerski JJ, et al. Hypercalcemia of malignancy due to
ectopic transactivation of the parathyroid hormone gene.
J Clin Endocrinol Metab 2006;91:580-3.
Tong CV, Hussein Z, Noor NM, Mohamad M, Ng WF. Use
of denosumab in parathyroid carcinoma with refractory
hypercalcemia. QJM 2015;108:49-50.
Hutchesson AC, Bundred NJ, Ratcliffe WA. Survival in
hypercalcaemic patients with cancer and co-existing primary
hyperparathyroidism. Postgrad Med J 1995;71:28-31.
Lee SH, Kim BH, Bae MJ, Yi YS, Kim WJ, Jeon YK, et al.
Concurrence of primary hyperparathyroidism and metastatic
breast carcinoma affected a parathyroid gland. J Clin
Endocrinol Metab 2013;98:3127-30.
Hussain N, Khan M, Natarajan A, Mohammedabdul M,
Mustafa U, Yedulla K, et al. A case of multiple myeloma
coexisting with primary hyperparathyroidism and review
of the literature. Case Rep Oncol Med 2013;2013:420565.
Inzucchi SE. Understanding hypercalcemia. Its metabolic
basis, signs, and symptoms. Postgrad Med 2004;115:69-70,
73-6.
Nakajima N, Ueda M, Nagayama H, Yamazaki M, Katayama Y.
Posterior reversible encephalopathy syndrome due to
hypercalcemia associated with parathyroid hormone-related
peptide: A case report and review of the literature. Intern Med
2013;52:2465-8.
Camara-Lemarroy CR, Gonzalez-Moreno EI, Ortiz-Corona Jde J,
Yeverino-Castro SG, Sanchez-Cardenas M, Nuñez-Aguirre S,
et al. Posterior reversible encephalopathy syndrome due to
malignant hypercalcemia: Physiopathological considerations.
J Clin Endocrinol Metab 2014;99:1112-6.

North American Journal of Medical Sciences | Nov 2015 | Volume 7 | Issue 11 |

491

[Downloaded free from http://www.najms.org on Friday, November 27, 2015, IP: 202.164.43.126]

Mirrakhimov: Hypercalcemia of malignancy
28. Lins LE. Reversible renal failure caused by hypercalcemia.
A retrospective study. Acta Med Scand 1978;203:309-14.
29. Caruana RJ, Buckalew VM Jr. The syndrome of distal renal
tubular acidosis. Clinical and laboratory findings in 58 cases.
Medicine Baltimore. 1988;67:84-99.
30. Gardner EC Jr, Hersh T. Primary hyperparathyroidism and
the gastrointestinal tract. South Med J 1981;74:197-9.
31. Wynn D, Everett GD, Boothby RA. Small cell carcinoma of
the ovary with hypercalcemia causes severe pancreatitis and
altered mental status. Gynecol oncol 2004;95:716-8.
32. Diercks DB, Shumaik GM, Harrigan RA, Brady WJ,
Chan TC. Electrocardiographic manifestations: Electrolyte
abnormalities. J Emerg Med 2004;27:153-60.
33. Ashizawa N, Arakawa S, Koide Y, Toda G, Seto S, Yano K.
Hypercalcemia due to Vitamin D intoxication with clinical
features mimicking acute myocardial infarction. Intern Med
2003;42:340-4.
34. Nishi SP, Barbagelata NA, Atar S, Birnbaum Y, Tuero E.
Hypercalcemia-induced ST-segment elevation mimicking
acute myocardial infarction. J Electrocardiol 2006;39:298-300.
35. Turhan S, Kilickap M, Kilinc S. ST segment elevation
mimicking acute myocardial infarction in hypercalcaemia.
Heart 2005;91:999.
36. Kiewiet RM, Ponssen HH, Janssens EN, Fels PW. Ventricular
fibrillation in hypercalcaemic crisis due to primary
hyperparathyroidism. Neth J Med 2004;62:94-6.
37. Lafferty FW. Differential diagnosis of hypercalcemia. J Bone
Miner Res 1991;6 Suppl 2:S51-9.
38. Ladenson JH, Lewis JW, McDonald JM, Slatopolsky E, Boyd JC.
Relationship of free and total calcium in hypercalcemic
conditions. J Clin Endocrinol Metab 1979;48:393-7.
39. Strodel WE, Thompson NW, Eckhauser FE, Knol JA.
Malignancy and concomitant primary hyperparathyroidism.
J Surg Oncol 1988;37:10-2.
40. Wong K, Tsuda S, Mukai R, Sumida K, Arakaki R.
Parathyroid hormone expression in a patient with metastatic
nasopharyngeal rhabdomyosarcoma and hypercalcemia.
Endocrine 2005;27:83-6.
41. Bilezikian JP. Primary hyperparathyroidism. Endocr Pract
2012;18:781-90.
42. Kannan S, Milas M, Neumann D, Parikh RT, Siperstein A,
Licata A. Parathyroid nuclear scan. A focused review on
the technical and biological factors affecting its outcome.
Clin cases miner bone metab 2014;11:25-30.
43. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related
protein and response to pamidronate in tumour-induced
hypercalcaemia. Lancet 1993;341:1611-3.
44. Wimalawansa SJ. Significance of plasma PTH-rp in
patients with hypercalcemia of malignancy treated with
bisphosphonate. Cancer 1994;73:2223-30.
45. Pecherstorfer M, Schilling T, Blind E, Zimmer-Roth I,
Baumgartner G, Ziegler R, et al. Parathyroid hormone-related
protein and life expectancy in hypercalcemic cancer patients.
J Clin endocrinol metab 1994;78:1268-70.
46. Ling PJ, A’Hern RP, Hardy JR. Analysis of survival
following treatment of tumour-induced hypercalcaemia with
intravenous pamidronate APD. Br J Cancer 1995;72:206-9.
47. Shivnani SB, Shelton JM, Richardson JA, Maalouf NM.
Hypercalcemia of malignancy with simultaneous elevation
in serum parathyroid hormone related peptide and
1,25-dihydroxy Vitamin D in a patient with metastatic renal
cell carcinoma. Endocr Pract 2009;15:234-9.

492

48. Hosking DJ, Cowley A, Bucknall CA. Rehydration in the
treatment of severe hypercalcaemia. Q J Med 1981;50:473-81.
49. LeGrand SB, Leskuski D, Zama I. Narrative review:
Furosemide for hypercalcemia: An unproven yet common
practice. Ann Intern Med 2008;149:259-63.
50. Vaughn CB, Vaitkevicius VK. The effects of calcitonin in
hypercalcemia in patients with malignancy. Cancer 1974;
34:1268-71.
51. Dumon JC, Magritte A, Body JJ. Nasal human calcitonin for
tumor-induced hypercalcemia. Calcif tissue Int 1992;51:18-9.
52. Wisneski LA. Salmon calcitonin in the acute management of
hypercalcemia. Calcif tissue Int 1990;46(Suppl):S26-30.
53. Austin LA, Heath H 3 rd . Calcitonin: Physiology and
pathophysiology. N Engl J Med 1981;304:269-78.
54. Xu XL, Gou WL, Wang AY, Wang Y, Guo QY, Lu Q, et al.
Basic research and clinical applications of bisphosphonates
in bone disease: What have we learned over the last 40 years?
J Transl Med 2013;11:303.
55. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A,
Hulley PA, et al. Bisphosphonates: An update on mechanisms
of action and how these relate to clinical efficacy. Ann N Y
Acad Sci 2007;1117:209-57.
56. Major P, Lortholary A, Hon J, Abdi E, Mills G, Menssen HD,
et al. Zoledronic acid is superior to pamidronate in the
treatment of hypercalcemia of malignancy: A pooled analysis
of two randomized, controlled clinical trials. J Clin Oncol
2001;19:558-67.
57. Pecherstorfer M, Steinhauer EU, Rizzoli R, Wetterwald M,
Bergström B. Efficacy and safety of ibandronate in the
treatment of hypercalcemia of malignancy: A randomized
multicentric comparison to pamidronate. Support care cancer
2003;11:539-47.
58. Gucalp R, Theriault R, Gill I, Madajewicz S, Chapman R,
Navari R, et al. Treatment of cancer-associated hypercalcemia.
Double-blind comparison of rapid and slow intravenous
infusion regimens of pamidronate disodium and saline alone.
Arch intern med 1994;154:1935-44.
59. Machado CE, Flombaum CD safety of pamidronate in
patients with renal failure and hypercalcemia. Clin nephrol
1996;45:175-9.
60. Davenport A, Goel S, Mackenzie JC. Treatment of
hypercalcaemia with pamidronate in patients with end stage
renal failure. Scand J Urol Nephrol 1993;27:447-51.
61. Trimarchi H, Lombi F, Forrester M, Elizondo C, Sawinski D,
Pereyra H, et al. Disodium pamidronate for treating severe
hypercalcemia in a hemodialysis patient. Nat clin pract
nephrol 2006;2:459-63.
62. Saad F, Brown JE, Van Poznak C, Ibrahim T, Stemmer SM,
Stopeck AT, et al. Incidence, risk factors, and outcomes of
osteonecrosis of the jaw: Integrated analysis from three
blinded active-controlled phase III trials in cancer patients
with bone metastases. Ann oncol 2012;23:1341-7.
63. Hanley DA, Adachi JD, Bell A, Brown V. Denosumab:
Mechanism of action and clinical outcomes. Int J Clin Pract
2012;66:1139-46.
64. Hu MI, Glezerman I, Leboulleux S, Insogna K, Gucalp R,
Misiorowski W, et al. Denosumab for patients with persistent
or relapsed hypercalcemia of malignancy despite recent
bisphosphonate treatment. J Natl Cancer Inst 2013;105:1417-20.
65. Adhikaree J, Newby Y, Sundar S. Denosumab should
be the treatment of choice for bisphosphonate refractory
hypercalcaemia of malignancy. BMJ Case Rep 2014;2014.
pii: bcr2013202861.

North American Journal of Medical Sciences | Nov 2015 | Volume 7 | Issue 11 |

[Downloaded free from http://www.najms.org on Friday, November 27, 2015, IP: 202.164.43.126]

Mirrakhimov: Hypercalcemia of malignancy
66. Karuppiah D, Thanabalasingham G, Shine B, Wang LM,
Sadler GP, Karavitaki N, et al. Refractory hypercalcaemia
secondary to parathyroid carcinoma: Response to high-dose
denosumab. Eur J Endocrinol 2014;171:K1-5.
67. Bech A, de Boer H. Denosumab for tumor-induced
hypercalcemia complicated by renal failure. Ann Intern Med
2012;156:906-7.
68. Cicci JD, Buie L, Bates J, van Deventer H. Denosumab
for the management of hypercalcemia of malignancy in
patients with multiple myeloma and renal dysfunction.
Clin lymphoma myeloma leuk 2014;14:e207-11.
69. Hu MI, Glezerman IG, Leboulleux S, Insogna K, Gucalp R,
Misiorowski W, et al. Denosumab for treatment of hypercalcemia
of malignancy. J Clin endocrinol metab 2014;99:3144-52.
70. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R,
Reid IR, et al. Denosumab for prevention of fractures in
postmenopausal women with osteoporosis. N Engl J Med
2009;361:756-65.
71. Adams JS. Vitamin D metabolite-mediated hypercalcemia.
Endocrinol metab clin north am 1989;18:765-78.
72. Fardet L, Flahault A, Kettaneh A, Tiev KP, Généreau T,
Tolédano C, et al. Corticosteroid-induced clinical adverse
events: Frequency, risk factors and patient’s opinion.
Br J Dermatol 2007;157:142-8.
73. Collins MT, Skarulis MC, Bilezikian JP, Silverberg SJ,
Spiegel AM, Marx SJ. Treatment of hypercalcemia secondary
to parathyroid carcinoma with a novel calcimimetic agent.
J Clin endocrinol metab 1998;83:1083-8.

74. Silverberg SJ, Rubin MR, Faiman C, Peacock M, Shoback DM,
Smallridge RC, et al. Cinacalcet hydrochloride reduces the
serum calcium concentration in inoperable parathyroid
carcinoma. J Clin endocrinol metab 2007;92:3803-8.
75. Warrell RP Jr, Bockman RS, Coonley CJ, Isaacs M,
Staszewski H. Gallium nitrate inhibits calcium resorption
from bone and is effective treatment for cancer-related
hypercalcemia. J Clin Invest 1984;73:1487-90.
76. Warrell RP Jr, Alcock NW, Bockman RS. Gallium nitrate
inhibits accelerated bone turnover in patients with bone
metastases. J Clin oncol 1987;5:292-8.
77. Hall TJ, Chambers TJ. Gallium inhibits bone resorption by a
direct effect on osteoclasts. Bone miner 1990;8:211-6.
78. Warrell RP Jr, Israel R, Frisone M, Snyder T, Gaynor JJ,
Bockman RS. Gallium nitrate for acute treatment of
cancer-related hypercalcemia. A randomized, double-blind
comparison to calcitonin. Ann Int Med 1988;108:669-74.
79. Cvitkovic F, Armand JP, Tubiana-Hulin M, Rossi JF,
Warrell RP Jr. Randomized, double-blind, phase II trial of
gallium nitrate compared with pamidronate for acute control
of cancer-related hypercalcemia. Cancer J 2006;12:47-53.
80. Koo WS, Jeon DS, Ahn SJ, Kim YS, Yoon YS, Bang BK.
Calcium-free hemodialysis for the management of
hypercalcemia. Nephron 1996;72:424-8.
81. Leehey DJ, Ing TS. Correction of hypercalcemia and
hypophosphatemia by hemodialysis using a conventional,
calcium-containing dialysis solution enriched with
phosphorus. Am J Kidney Dis 1997;29:288-90.

North American Journal of Medical Sciences | Nov 2015 | Volume 7 | Issue 11 |

493

